1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
653DA5AEC7C1B295C85257F76004CDA46
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-internal-thought-leader-management-medical-affairs-resourcing-spend-allocations
18
19
203.90.12.112
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Thought Leader Services

Internal Thought Leader Management: Medical Affairs Resourcing and Spend Allocations

ID: 5405


Features:

13 Info Graphics

10 Data Graphics

200 Metrics


Pages/Slides: 33


Published: 2016


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Internal Thought Leader Management: Medical Affairs Resourcing and Spend Allocations"

STUDY OVERVIEW

The pharmaceutical industry is constantly changing, and to navigate this new landscape pharmaceutical leaders are focusing on establishing and maintaining deep relationships with thought leaders. Paramount to this effort is having in place internal policies and practices that are focused on effectively managing these critical relationships.


Best Practices, LLC conducted a benchmark study that addressed how the industry is adjusting its approach to organizing, staffing and managing thought leader relationships.

The study provides insights and benchmarks that illustrate how leading pharma and biotech companies organize and structure their Medical Affairs capabilities. In addition, the study examines resource levels for effective Medical Affairs organizations and identifies the critical requirements to create strong Medical Affairs capabilities.

This study will inform medical affairs leaders on current trends and practices on these issues.

Data in this study is presented in segments by company size and global vs. US only.


KEY TOPICS

  • Medical Affairs Structure and Leadership
  • Medical Affairs Spend Allocation and Importance of Functions
  • Medical Affairs Spend Ratios
KEY METRICS
  • Medical Affairs Structure
  • Challenges and Success Factors to Build Strong Medical Affairs Capabilities
  • Importance and Spend Allocation for Medical Affairs
  • Medical Affairs Spending Breakout
  • Medical Affairs Resource Level Change
  • Medical Affairs Outsourcing Levels
  • Importance of Medical Affairs Functions
  • Issues Affecting Change in Medical Affairs Importance
  • Revenue Per Medical Affairs FTE
  • Medical Affairs Spend Per In-Market Product
  • Medical Affairs Spend Per Pipeline Product
  • Medical Affairs Spend Per Medical Affairs FTE
  • Labor Spend


SAMPLE KEY FINDING

  • Spend Allocation: Field-Based Medical Teams has the largest share of spend and Medical Affairs participants think that this is an area that is getting much more important. However, we didn't see this type of alignment (importance perception and spend allocation) in three Medical Affairs functions:
1. Medical Education
2. Outcomes Research / Real World Data
3. Medical Communication & Publication


METHODOLOGY

Thirty-one survey responses from Medical Affairs leaders at 27 biopharmaceutical companies. This report captures insights on Large , Mid-Size and Small companies segments as well as on companies from Global and US-only regions.

Industries Profiled:
Biopharmaceutical; Biotech; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care; Clinical Research; Laboratories


Companies Profiled:
Alkermes; Allergan; Baxalta; Bayer; Celldex Therapeutics; CSL Behring; Genentech; Genzyme; GW Pharmaceuticals; Indivior; Jazz Pharmaceuticals; Mesoblast; Neurocrine Biosciences; Norgine; Novo Nordisk; Perrigo Company; Pfizer; ProStrakan; Sanofi; Santen; Shire; Stallergenes; Sunovion; Teva Pharmaceutical Industries Ltd; Theravance; Tris Pharma; UCB Pharma


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.